Clinical trial
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients…
NCT00305864 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00305864 |
|---|---|
| Title | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
| Official title | A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Radiation Therapy Oncology Group |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma |
| Intervention type | Drug, Radiation |
| Interventions | 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide |
| Enrollment | 118 |
| Start date | Feb 9, 2006 |
| Primary completion | Feb 16, 2011 |
| Completion | Mar 15, 2011 |
| First posted | Mar 22, 2006 |
| Last update posted | Mar 5, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: